Skip to main content

Telecom stocks tumble after Jio launches new post-paid plans; Airtel, Vodafone Idea fall 7-8%

Telecom stocks came under pressure after rival Reliance Jio launched a range of postpaid plans. Bharti Airtel, Vodafone Idea and Bharti Infratel shed 7-8 percent each.

S&P BSE Telecom tanked over 7 percent intraday on September 23. Bharti Airtel and Bharti Infratel were the top losers with each falling over 7 percent during the session.

Telecom stocks are under pressure since morning after Reliance Jio launched a range of postpaid plans.

The share price of Bharti Airtel was down over 8 percent and was trading at Rs 433.45, down Rs 37.60, or 7.98 percent at 13:55 hours. It was trading with volumes of 1,782,532 shares, compared to its five day average of 755,399 shares, an increase of 135.97 percent.

Vodafone Idea was trading Rs 9.32, down Rs 0.93, or 9.07 percent. It has touched an intraday high of Rs 10.20 and an intraday low of Rs 9.23. The scrip was trading with volumes of 61,186,345 shares, compared to its five day average of 53,710,660 shares, an increase of 13.92 percent.

Bharti Infratel share price at 13:59 hrs was trading at Rs 164.85, down Rs 15.45, or 8.57 percent. It touched an intraday low of Rs 164.60.

Bharti Airtel was one of the most active stocks on NSE with 5,94,53,689 shares being traded while Vodafone Idea was trading with 42,19,86,944 shares.



Reliance Jio has introduced new postpaid plans called JioPostpaid Plus that offers a free subscription to OTT platforms Amazon Prime, Disney+ Hotstar, and Netflix and a host of other benefits. With tariffs ranging between Rs 399 and Rs 1,499, the latest range of Jio postpaid plans will be available from September 24 in Jio Stores and via home delivery, which will come free with activation.

Bharti Infratel Chairman Akhil Gupta said setting a floor price as a temporary measure can help restore the financial health of the industry. "A floor price should be fixed at least for the next three to four years. Post that, as things settle down, it can be taken off.

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more